PuSH - Publikationsserver des Helmholtz Zentrums München

Stemmer, K. ; Müller, T.D.

GLP-1-Mimetika – wegweisend zur Behandlung von Diabetes und Adipositas.

GLP-1 mimetics - pioneering for the treatment of diabetes and obesity.

BioSpektrum 29, 137-139 (2023)
Verlagsversion DOI
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
Most obese patients would benefit from 5–10 % of weight loss but fail when using non-surgical approaches. The recent development of two anti-obesity drugs may change that therapeutic gap. Patients receiving long-acting glucagon-like peptide 1 (GLP1) agonist semaglutide achieve weight loss above 10 %. With tirzepatide, a co-agonist for GLP-1 and the gastric inhibitory polypeptide (GIP) receptor, more than 50 % of the patients even lose above 20 %, which rivals the efficacy of surgical interventions.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
ISSN (print) / ISBN 0947-0867
e-ISSN 1868-6249
Zeitschrift BioSpektrum
Quellenangaben Band: 29, Heft: 2, Seiten: 137-139 Artikelnummer: , Supplement: ,
Verlag Springer
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)